Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| I9O-MC-AABA | Other Identifier | Eli Lilly and Company | |
| 2017-001242-10 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given together with LY9999QS compared to LY3074828 alone. The tolerability of the different formulations will also be evaluated and information about any side effects experienced will be collected.
Screening is required within 28 days prior to the start of the study. For each participant the total duration of the clinical trial will be approximately 13 weeks, not including screening.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LY3074828 - Treatment 1 | Experimental | Single intravenous (IV) dose of LY3074828 |
|
| LY900021 - Treatment 2 | Experimental | Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS) |
|
| LY900021 - Treatment 3 | Experimental | Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS) |
|
| LY900021 - Treatment 4 | Experimental | Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LY3074828 | Biological | Administered IV |
| |
| LY900021 |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3074828 | PK: AUC of LY3074828 | Baseline through Day 85 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. | Leeds | United Kingdom |
Not provided
| ID | Term |
|---|---|
| C000708407 | mirikizumab |
Not provided
Not provided
Not provided
Treatments 2 and 3 of LY900021 will be administered in parallel with LY3074828. Treatments 2, 3, and 4 of LY900021 will be administered sequentially pending a safety review after administration of Treatments 2 and 3.
Not provided
Not provided
Open
Not provided
| Biological |
Administered SC |
|